Launch the Re-Tain product
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 30 Sep 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we are planning for product launch during the third quarter of 2021 in the event of a first-time approval from the FDA”
What we found
Evidence strength A What the grades mean
The company did not launch Re-Tain by the third quarter of 2021, as it had not yet received the final FDA approval required for commercial sales.
-
A Immucell Corp. 10-Q filed 2021-11-15
“approval of the CMC Technical Section is the fifth and final significant step required before Re-Tain® product sales can be initiated in the United States.” ✓ confirmed on the page
-
A Immucell Corp. 10-Q filed 2022-05-12
“The commercial introduction of this product in the United States requires us to obtain FDA approval. We have disclosed a timeline of events that could lead to product approval during the fourth quarter of 2022.” ✓ confirmed on the page
Market reaction: the shares moved -1.9% against the S&P 500 over the three sessions around the disclosure (12 Nov 2021 to 17 Nov 2021). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Re-Tain product
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: in the event of a first-time approval from the FDA
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Immucell Corp.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ICCC-021293 · Corrections policy